RAS LSS Consulting’s Post

The Economic Survey 2024 highlights the future growth of India's #pharma sector, emphasizing skill advancement, #innovation, and a strong #supplychain. With the industry projected to reach $130 billion by 2030, key areas include enhanced #API manufacturing and sustained export growth. #EconomicSurvey2024 #PharmaGrowth #Formulations #Innovation #SupplyChain #IndiaPharma #Exports #PLI #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #MarketExpansion

Day - 2 |  "Summary of the Economic Survey FY-24 regarding India’s pharmaceutical sector" In FY24, India’s pharmaceutical sector increased its export share to 6.4% and export value to $27.9 billion, up from $19.1 billion in FY19 (8% CAGR). The industry is valued at $50 billion and the third-largest globally by volume, known for its dominance in global generics. India offers approximately 60,000 generic brands across 60 therapeutic categories, contributing 20% to global generic drug exports. 8 of the top 20 global generic companies are based in India. Despite these advances, India remains dependent on imports for active pharmaceutical ingredients (APIs), especially antibiotics. The government's Production-Linked Incentive (PLI) schemes are helping to reduce this reliance by supporting the domestic production of certain APIs and medical devices. Bulk drug exports exceeded imports, with exports totalling Rs 39,632 crore and imports of Rs 37,722 crore in FY24. Initiatives are taken to ensure access to high-quality generic medicines at affordable prices through the Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs). With more than 12,500 PMBJKs established, serves both the general population and economically disadvantaged groups. Looking ahead, the sector is expected to grow to $130 billion by 2030, driven by innovation in biopharmaceuticals, skill development, and a strong supply chain, positioning India as a key player in global healthcare #Linkedin #Pharma #Finance Parth Verma The Valuation School

𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 𝐔𝐩𝐝𝐚𝐭𝐞 𝐨𝐧 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐏𝐋𝐈 𝐒𝐜𝐡𝐞𝐦𝐞 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 📅 Significant achievements have been reported under the "Production Linked Incentive (PLI) Scheme," which aims to enhance domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs). Key highlights include: ✅ 32 Projects Completed: These projects have established a cumulative installed capacity of 56,679 metric tons per annum, reinforcing India’s position in the global pharmaceutical market. 💰 Investment Exceeds Targets: Total investments have reached ₹4,024 crores, surpassing the initial target of ₹3,938 crores, indicating strong stakeholder engagement. 🏢 Focus on MSMEs: Among the 48 selected projects, 13 are being executed by 10 Micro, Small, and Medium Enterprises (MSMEs), highlighting the commitment to fostering innovation and growth within smaller businesses. 📈 Production Timeline: The operational period of the scheme spans from FY 2022-23 to FY 2028-29, designed to reduce import dependence and improve supply chain resilience. 🌍 Diverse State Impact: With 249 applications received, projects are distributed across multiple states, including: 𝐀𝐧𝐝𝐡𝐫𝐚 𝐏𝐫𝐚𝐝𝐞𝐬𝐡: Key players such as Lyfius Pharma and Hetero Drugs are driving advancements. 𝐆𝐮𝐣𝐚𝐫𝐚𝐭: Macleods Pharmaceuticals is leading in bulk drug production. 𝐌𝐚𝐡𝐚𝐫𝐚𝐬𝐡𝐭𝐫𝐚: Sadhana Nitro Chem and other MSMEs are making significant contributions. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐦𝐩𝐚𝐜𝐭: The completion of these projects is expected to enhance the availability of critical pharmaceuticals, reduce reliance on imports, and stabilize pricing. By boosting local manufacturing, the scheme is set to strengthen India’s self-sufficiency in healthcare products, contributing to a more resilient supply chain. This initiative is poised to foster competitive pricing and greater innovation in the sector, benefiting both manufacturers and consumers alike. Support for the continued growth of the chemicals used in the pharmaceutical sector is a significant factor for Indian chemical market growth. 🇮🇳💊 #Pharmaceuticals #PLI #MakeInIndia #MSMEs #Healthcare #Sustainability Karan Chechi | Alwin Samuel | Shaurya Singh | TechSci Research | ChemAnalyst

India's Pharma Growth Surge: Key Factors Driving Success! India’s pharmaceutical industry is on an incredible growth trajectory, and several key factors are fueling this remarkable expansion. The Indian government is playing a crucial role in the growth of the pharmaceutical sector through several strategic initiatives. Here’s how they’re making a difference: Pharma Vision 2025: Aiming to make India a global leader in pharmaceuticals by enhancing R&D, innovation, and manufacturing capabilities. Production Linked Incentive (PLI) Scheme: Offering incentives up to $6 B to boost domestic production of critical drugs and reduce dependency on imports. National Biopharma Mission: A $600 M initiative focused on supporting research and development in biotechnology and bio-manufacturing. Ayushman Bharat Scheme: Expanding healthcare access to over 500 M Indians, creating a substantial demand for pharmaceuticals and boosting industry growth. E-Pharma Regulations: Implementing policies to streamline and regulate online pharmaceutical sales, ensuring safety and expanding market reach. Infrastructure Development: Investing in state-of-the-art pharma parks and industrial zones to enhance manufacturing efficiency and capabilities. Key highlights of India Pharma: Innovative R&D: 1,500+ drug patents filed in 2023. $7 billion in biotech investments by 2025. Generic Drug Leader: 20% of global generic medicines supplied. 190 US FDA-approved formulation facilities from 106 companies. Regulatory Excellence: 150+ WHO-prequalified products. Stringent CDSCO standards. Market Expansion: $100 billion projected market size by 2025. 14% increase in pharmaceutical exports. Healthcare Investment: $50 billion boost in 2024 health spending. India’s pharma industry isn’t just growing; it's transforming the global healthcare landscape. Stay tuned as we continue to lead and innovate! #IndiaPharma #GlobalHealth #Innovation #FDA #India #Pharma #PharmaceuticalExcellence #Export #MakeInIndia #PharmacyOfWorld #InvestIndia #InvestInIndia #Big #Invest #Make #Manufacturing #China #USA #Healthcare #BigPharma #Generics Indian Pharmaceutical Alliance; Pharmexcil (Pharmaceuticals Export Promotion Council of India); IPEC India - International Pharmaceutical Excipients’ Council of India; FDA; Invest India; Indian Pharmaceutical Association

🌟 The Indian Pharma Sector: A Growth Story Worth Watching 💊💉🩺🏥 India’s pharmaceutical industry is making waves yet again, with analysts predicting a period of robust growth. A recent report by Motilal Oswal highlights the immense opportunities this sector presents for businesses. Here are some key insights driving this optimism: 1️⃣ Global Demand Surge: As the largest supplier of generic medicines, Indian pharmaceutical companies are uniquely positioned to cater to the growing healthcare needs across developed and emerging markets. 2️⃣ Innovation at the Core: With increased focus on R&D, biosimilars, specialty drugs, and high-margin products, Indian pharma is building a reputation for competing successfully in niche markets. 3️⃣ Favorable Policy Landscape: Government initiatives and streamlined regulatory frameworks have further bolstered the sector’s capacity to scale manufacturing and exports. 4️⃣ Resilience Amid Challenges: The COVID-19 pandemic tested the industry’s adaptability, and Indian pharma proved its mettle by meeting global healthcare demands efficiently and effectively. 💡 What does this mean for the future? The Indian pharma story isn’t just about market expansion—it’s about making a meaningful impact on global healthcare through innovation, accessibility, and quality. As someone who’s passionate about Pharma, tracking industry trends and fostering growth, I’m inspired by this narrative. Businesses have the chance to collaborate, innovate, and expand globally. 🔎 Let’s discuss: What challenges do you foresee for the Indian pharmaceutical industry in the next decade? Which companies or innovations do you think will lead the way? How can businesses and investors maximize this growth potential? This is an exciting time for the Indian pharmaceutical sector, and I’d love to hear your thoughts! 🚀 #IndianPharma #HealthcareInnovation #monark #export #PharmaGrowth #InvestmentOpportunities #Leadership #monarkbicare

"BHARAT POISED FOR PHARMA SUPREMACY" From humble beginnings, India’s pharmaceutical industry has undergone a metamorphosis, transforming into the world’s medicine cabinet. Earning the illustrious title of “pharmacy of the world,” this sector is experiencing a growth surge unlike any other. Imagine this: a USD 40 billion industry in 2021, projected to balloon to a staggering USD 130 billion by 2030, with some analysts whispering a future worth a mind-numbing USD 450 billion by 2047. This isn’t alchemy, it’s the real deal. India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India’s biotechnology industry crossed USD 80.12 billion, growing 14 per cent from the previous year. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8 per cent, primarily driven by an 8 per cent increase in exports and a 6 per cent rise in the domestic market. In the global pharmaceuticals sector, India is a significant and rising player. According to IBEF, India is the world’s largest supplier of generic medications, accounting for 20 per cent of the worldwide supply by volume and supplying about 60 per cent of the global vaccination demand The PLI-I scheme of the government identified 48 critical bulk drugs for manufacturing locally. The success of this inaugural scheme led the government to launch the Rs. 15,000 crore PLI-II scheme which envisages to increase our cost competitiveness for medicines and medical products in the international market Source : Logisticandscm.com

Indian pharma industry eyes 9% annual growth on strong domestic and export markets, says report #IndianPharma #PharmaGrowth #ExportMarkets #DomesticMarkets #PharmaIndustry #AnnualGrowth #MarketReport #IndianEconomy #PharmaExports #IndustryInsights

Day 3 of 100 days of finance series challenge sharing insights on Finance. Understanding About India's Pharmaceutical Industry and its growth drivers ◽ The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volumes, eleventh in terms of medicine spending and fourteen it's terms of value. ◽ The Indian pharmaceutical market (IPM) which is valued over $24 billion grew at 7%, The Global pharma market is expected to grow at CAGR 5.9% where as the Indian pharma market is expected to grow at 9.6%. ◽ The Indian pharma industry is also known as " Pharmacy of the World" Supplying 20% of the world generic medicines and 60% of the worlds vaccines. ◽ What factor contribute to the Indian pharmaceutical industry growing at higher CAGR then the Global pharmaceutical industry? 1) Cost Efficiency- India has an Competitive advantage due to lower labor Cost , making it a major exporter of affordable generic drug. 2) Strong Domestic Demand- India's large population, rising income and increasing healthcare awareness has given boost to the industry. 3) Research and Development- Indian pharmaceutical companies are Increasingly investing in R&D to expand their global footprints. 4) Favorable Government Policies - Schemes like "PLI 1.0 bulk drug park" and " PLI 2.0 schemes" support a lot in the growth of the Pharma i industry. #day3 #Pharmasector #valueaddition #Finance #

𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐅𝐢𝐥𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $26.2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/dvHBdbNe The size of global 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐟𝐢𝐥𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐦𝐚𝐫𝐤𝐞𝐭 𝐈𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $13.5 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $26.2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 14.2% from 2023 to 2028 Emerging countries such as #China, #India, #Brazil, and #Mexico are expected to offer significant growth opportunities for players operating in the global market. The booming #biopharmaceutical sector in these countries, an increased risk of pandemics (such as swine flu and COVID-19), less-stringent regulatory guidelines, growing economic strength and population, and the low manufacturing cost advantage are the major factors that are attracting market players to set up and expand their presence in these countries. Emerging economies are densely populated, with the population mark crossing 2 billion in recent years (Source: The World Bank Group). This has created opportunities for the expansion of the pharmaceutical industry in this region, which in turn is driving the demand for pharmaceutical filtration products. #China is estimated to be a high-growth market for #bioprocessing products due to the growing government support and private investments in the country. Companies in China are increasingly making biologics-related investments and hiring a skilled workforce for their operations. Also, R&D investments in markets such as #India and #Brazil have increased significantly over the last few years. To capitalize on the available growth opportunities, key players are establishing new facilities, R&D centers, and innovation centers in these emerging countries. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Merck KGaA, Darmstadt, Germany, Danaher Corporation, Sartorius , 3M , Thermo Fisher Scientific

Indian pharma & biotech cos confident of new US President Trump's support to Indian pharma Indian pharma and biotech companies are confident that under the new US President Donald Trump, its strengths in high quality generics manufacture and export will continue to command respect. This view is based on the fact that when Donald Trump became the US President his government continued a favourable relationship, particularly recognizing India's role in global drug production. US remains a powerhouse in pharmaceutical research and development. With a robust infrastructure, significant investment in biotechnology and pharmaceutical companies, along with a supportive regulatory environment, the US continues to lead the way in bringing new drugs and therapies to market. Further, the presence of leading research institutions, academic centres, and pharmaceutical companies contribute to this leadership position. Furthermore US pharmaceutical market is not only about innovation but also provides a thriving generic drug market. Generic drugs offer cost-effective alternatives to brand-name medications, helping to reduce healthcare expenses for patients. Overall, the US-India pharmaceutical relationship is mutually beneficial. India is playing a key role in supplying affordable medications and the US providing an attractive market with a stringent regulatory environment for companies to prove their mettle. If you are a fresher in the Export field. 🔥Join our Startup Export Training.  For more details. 💰 Visit https://zurl.co/UuWY or Contact 7598 404848 If you have basic about the Export field 🔥Join our Advanced Realtime Export Training. For more details. 💰Visit https://zurl.co/dukq or Contact 7598 786858 #export #exporter #exportimport #exports #importexport #exportproduct #exportbusiness #exportbag #exportquality #exportindia #exporting #exportimportdata #eximedia #indiaexport #indiaexports #indiaexporters #indiaexportimport #indiabusiness #ucorpexim #exporttraining#exportstraining #exportertraining #exporterstraining #importtraining #importstraining #importertraining #importerstraining #ucorp